In a double-blind study of n=16 chronic insomniac patients, intravenous DSIP at 25 nmol/kg over 3 nights was associated with higher sleep efficiency and shorter sleep latency (the time it takes to fall asleep) compared with placebo, but the effects were described as weak [4]
One sip closer to control, every single day
3) controlling autonomic function [97,98,99] has sparked considerable interest in the cardiovascular biology of native GLP-1 and GLP-1RA
Observations in murine models of GHRH gene ablation point to possible normalization of growth indicators, including body weight, bone length, and lean mass, with concurrent increases in pituitary RNA and GH mRNA levels
Many patients may find that their out-of-pocket costs are lower with the generic option, making it a good alternative for patient access to GLP-1 therapy